Tvardi Therapeutics, Inc. (FRA:69C)
Germany · Delayed Price · Currency is EUR 3.065
+0.310 (11.25%)
Last updated: Nov 27, 2025, 8:02 AM CET
Tvardi Therapeutics Company Description
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 12 |
| CEO | Imran Alibhai |
Contact Details
Address: 3 Sugar Creek Center Boulevard Sugar Land, Delaware 77478 United States | |
| Phone | 713 489 8654 |
| Website | tvarditherapeutics.com |
Stock Details
| Ticker Symbol | 69C |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Imran Alibhai | Chief Executive Officer |
| Dan Conn | Chief Financial Officer |